Skip to main content

Zachary Wallace

Dr Zachary Wallace is a rheumatologist and clinical epidemiology researcher at Massachusetts General Hospital (MGH) and an Assistant Professor of Medicine at Harvard Medical School in Boston, Massachusetts, USA. Dr. Wallace conducts clinical epidemiology research in multi-system rheumatic diseases, particularly IgG4-related disease and ANCA-associated vasculitis, and the impact of COVID-19 on patients with rheumatic disease.

His ultimate goal is to understand how we can leverage disease- and patient-specific factors to guide treatment decisions in a way that maximize patient-oriented outcomes. He is a member of the Steering Committee of the COVID-19 Global Rheumatology Alliance, an international organization studying the impact of COVID-19 on patients with rheumatic diseases and the broader rheumatology community.

His research group is located in the Clinical Epidemiology Program at the Mongan Institute of MGH. He is a member of the Vasculitis and Glomerulonephritis Center as well as the Autoimmune Center of Excellence in IgG4-RD at MGH. His research has been funded by the National Institutes of Health, the Rheumatology Research Foundation, the Executive Committee on Research at MGH, and industry.


Latest contributions from Zachary Wallace

Zachary Wallace

18-01-2022 | COVID-19 | Feature | Article

COVID-19: Lessons learned for rheumatology practice

Zachary Wallace discusses the changes that have occurred in rheumatology practice as a result of the COVID-19 pandemic, and explores what lessons can be taken forward to improve patient care.

Jeffrey Sparks and Zachary Wallace

02-06-2021 | EULAR 2021 | Conference coverage | Video

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

Jeffrey Sparks and Zachary Wallace talk about the potential for COVID-19 being more severe in rheumatoid arthritis patients treated with rituximab or JAK inhibitors rather than TNF inhibitors.